2. Academic Validation
  3. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment

Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment

  • Mol Cell. 2019 Mar 7;73(5):1001-1014.e8. doi: 10.1016/j.molcel.2018.11.028.
Saranna Fanning 1,  Aftabul Haque 2,  Thibaut Imberdis 3,  Valeriya Baru 2,  M Inmaculada Barrasa 2,  Silke Nuber 3,  Daniel Termine 2,  Nagendran Ramalingam 3,  Gary P H Ho 3,  Tallie Noble 4,  Jackson Sandoe 2,  Yali Lou 2,  Dirk Landgraf 2,  Yelena Freyzon 2,  Gregory Newby 5,  Frank Soldner 2,  Elizabeth Terry-Kantor 3,  Tae-Eun Kim 3,  Harald F Hofbauer 6,  Michel Becuwe 7,  Rudolf Jaenisch 5,  David Pincus 2,  Clary B Clish 8,  Tobias C Walther 9,  Robert V Farese Jr 10,  Supriya Srinivasan 11,  Michael A Welte 12,  Sepp D Kohlwein 6,  Ulf Dettmer 13,  Susan Lindquist 14,  Dennis Selkoe 15
Affiliations

Affiliations

  • 1 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
  • 2 Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
  • 3 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  • 4 Mira Costa College, 1 Barnard Drive, Oceanside, CA 92056, USA.
  • 5 Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, MIT, Cambridge, MA 02139, USA.
  • 6 Institute of Molecular Biosciences, BioTechMed-Graz, University of Graz, 8010 Graz, Austria.
  • 7 Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA.
  • 8 Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • 9 Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA; Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA; HHMI, Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA.
  • 10 Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA; Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA; Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
  • 11 Department of Chemical Physiology and The Dorris Neuroscience Center, 1 Barnard Drive, Oceanside, CA 92056, USA; The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
  • 12 Department of Biology, University of Rochester, Rochester, NY 14627, USA.
  • 13 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: udettmer@bwh.harvard.edu.
  • 14 Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, MIT, Cambridge, MA 02139, USA; HHMI, Department of Biology, MIT, Cambridge, MA 02139, USA.
  • 15 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address: dselkoe@bwh.harvard.edu.
PMID: 30527540 DOI: 10.1016/j.molcel.2018.11.028
Abstract

In Parkinson's disease (PD), α-synuclein (αS) pathologically impacts the brain, a highly lipid-rich organ. We investigated how alterations in αS or lipid/fatty acid homeostasis affect each other. Lipidomic profiling of human αS-expressing yeast revealed increases in oleic acid (OA, 18:1), diglycerides, and triglycerides. These findings were recapitulated in rodent and human neuronal models of αS dyshomeostasis (overexpression; patient-derived triplication or E46K mutation; E46K mice). Preventing lipid droplet formation or augmenting OA increased αS yeast toxicity; suppressing the OA-generating Enzyme stearoyl-CoA-desaturase (SCD) was protective. Genetic or pharmacological SCD inhibition ameliorated toxicity in αS-overexpressing rat neurons. In a C. elegans model, SCD knockout prevented αS-induced dopaminergic degeneration. Conversely, we observed detrimental effects of OA on αS homeostasis: in human neural cells, excess OA caused αS inclusion formation, which was reversed by SCD inhibition. Thus, monounsaturated fatty acid metabolism is pivotal for αS-induced neurotoxicity, and inhibiting SCD represents a novel PD therapeutic approach.

Keywords

Parkinson’s disease; alpha-synuclein; diglyceride; inclusions; lipid droplets; oleic acid; stearoyl-CoA-desaturase; synucleinopathy; tetramer; triglyceride; unsaturated fatty acid.

Figures
Products